Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q5BJH7

UPID:
YIF1B_HUMAN

ALTERNATIVE NAMES:
YIP1-interacting factor homolog B

ALTERNATIVE UPACC:
Q5BJH7; H7BXS8; Q5JPC2; Q8WY70; Q96C02; Q96IC4

BACKGROUND:
The Protein YIF1B, alternatively named YIP1-interacting factor homolog B, is pivotal in the regulation of vesicle-mediated transport between the endoplasmic reticulum and the Golgi. Its role extends to ensuring the structural integrity of these organelles and facilitating the precise targeting of receptors to neuronal dendrites. Additionally, YIF1B contributes to the assembly of primary cilia and sperm flagella, indicating its broad impact on cellular function and development.

THERAPEUTIC SIGNIFICANCE:
Given its critical involvement in Kaya-Barakat-Masson syndrome, a disorder marked by profound neurodevelopmental challenges, Protein YIF1B emerges as a key target for therapeutic intervention. Exploring the functions and mechanisms of YIF1B offers promising avenues for the development of novel treatments aimed at alleviating the symptoms of this syndrome and enhancing the quality of life for affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.